TY  - JOUR
A1  - Hopfner, Franziska
A1  - Schormair, Barbara
A1  - Knauf, Franziska
A1  - Berthele, Achim
A1  - Tölle, Thomas R.
A1  - Baron, Ralf
A1  - Maier, Christoph
A1  - Treede, Rolf-Detlef
A1  - Binder, Andreas
A1  - Sommer, Claudia
A1  - Maihöfner, Christian
A1  - Kunz, Wolfram
A1  - Zimprich, Friedrich
A1  - Heemann, Uwe
A1  - Pfeufer, Arne
A1  - Näbauer, Michael
A1  - Kääb, Stefan
A1  - Nowak, Barbara
A1  - Gieger, Christian
A1  - Lichtner, Peter
A1  - Trenkwalder, Claudia
A1  - Oexle, Konrad
A1  - Winkelmann, Juliane
T1  - Novel SCARB2 mutation in Action Myoclonus-Renal Failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features
JF  - BMC Neurology
N2  - Background: 

Action myoclonus-renal failure syndrome is a hereditary form of progressive myoclonus epilepsy associated with renal failure. It is considered to be an autosomal-recessive disease related to loss-of-function mutations in SCARB2. We studied a German AMRF family, additionally showing signs of demyelinating polyneuropathy and dilated cardiomyopathy. To test the hypothesis whether isolated appearance of individual AMRF syndrome features could be related to heterozygote SCARB2 mutations, we screened for SCARB2 mutations in unrelated patients showing isolated AMRF features. 

Methods: 

In the AMRF family all exons of SCARB2 were analyzed by Sanger sequencing. The mutation screening of unrelated patients with isolated AMRF features affected by either epilepsy (n = 103, progressive myoclonus epilepsy or generalized epilepsy), demyelinating polyneuropathy (n = 103), renal failure (n = 192) or dilated cardiomyopathy (n = 85) was performed as high resolution melting curve analysis of the SCARB2 exons. 

Results: 

A novel homozygous 1 bp deletion (c.111delC) in SCARB2 was found by sequencing three affected homozygous siblings of the affected family. A heterozygous sister showed generalized seizures and reduction of nerve conduction velocity in her legs. No mutations were found in the epilepsy, renal failure or dilated cardiomyopathy samples. In the polyneuropathy sample two individuals with demyelinating disease were found to be carriers of a SCARB2 frameshift mutation (c.666delCCTTA). 

Conclusions: 

Our findings indicate that demyelinating polyneuropathy and dilated cardiomyopathy are part of the action myoclonus-renal failure syndrome. Moreover, they raise the possibility that in rare cases heterozygous SCARB2 mutations may be associated with PNP features.
KW  - Demyelinating peripheral neuropathy
KW  - Beta-glucocerebrosidase
KW  - Epilepsy
KW  - LIMP-2
KW  - Mice
Y1  - 2011
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141209
VL  - 11
IS  - 134
ER  - 
TY  - JOUR
A1  - Lindhoff-Last, Edelgard
A1  - Birschmann, Ingvild
A1  - Bidenharn, Antonia J.
A1  - Kuhn, Joachim
A1  - Lindau, Simone
A1  - Konstantinides, Stavros
A1  - Grottke, Oliver
A1  - Nowak-Göttl, Ulrike
A1  - Lucks, Jessica
A1  - Zydek, Barbara
A1  - Heymann, Christian von
A1  - Sümnig, Ariane
A1  - Beyer-Westendorf, Jan
A1  - Schellong, Sebastian
A1  - Meybohm, Patrick
A1  - Greinacher, Andreas
A1  - Herrmann, Eva
T1  - Pharmacokinetics of phenprocoumon in emergency situations – results of the prospective observational RADOA-registry (reversal agent use in patients treated with direct oral anticoagulants or vitamin K antagonists registry)
JF  - Pharmaceuticals
N2  - Background: Phenprocoumon has been used as an oral anticoagulant in patients with thromboembolic disease for more than 40 years. So far its pharmacokinetics have not been analyzed in emergency situations. Methods: Phenprocoumon-treated patients with major bleeding or urgent surgery were included in a prospective, observational registry. Phenprocoumon drug concentrations were analyzed in samples, collected as part of routine care using ultraperformance liquid chromatography tandem mass spectrometry. Moreover, anticoagulant intensity and drug half-life (t1/2) were calculated. Results: 115 patients were included. Phenprocoumon levels declined over time with a half-life of 5.27 and 5.29 days in patients with major bleedings (n = 82) and with urgent surgery (n = 33). Baseline phenprocoumon levels were 2.2 times higher in the bleeding group compared to the surgery group (1.92 vs. 0.87 ng/mL, p < 0.0001). International normalized ratio (INR) values decreased rapidly during the first 24 h. In 27.6% of patients a rebound of INR (recurrent increase > 1.5) was observed which was associated with significantly increased bleeding rates (22% vs. 4.2% in patients with or without INR rebound, p = 0.012). Conclusions: In emergency situations, the long half-life of phenprocoumon may cause INR rebound and associated recurrent bleedings. Optimal management may need to include repeated vitamin K supplementation over days.
KW  - phenprocoumon
KW  - pharmacokinetics
KW  - emergency
KW  - major bleeding
KW  - urgent surgery
KW  - INR rebound
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-297226
SN  - 1424-8247
VL  - 15
IS  - 11
ER  -